$\mathtt{Q^2SAR}$: overcoming classical bottlenecks in drug discovery via quantum multiple kernel learning

Quantitative Structure-Activity Relationship ($\mathtt{QSAR}$) modeling is a foundational computational methodology in early-stage drug discovery, heavily relied upon for predicting compound toxicity, bioavailability, and therapeutic potential. However, classical methods often struggle to effectively map the highly complex, non-linear, and high-dimensional interactions inherent in molecular data, leading to reduced predictive accuracy and costly late-stage clinical failures. In this paper, we present a Quantum Multiple Kernel Learning ($\mathtt{QMKL}$) framework, dubbed Next-Gen $\mathtt{Q^2SAR}$, that leverages Quantum Support Vector Machines ($\mathtt{QSVMs}$) to overcome these classical limitations. By encoding molecular descriptors into exponentially large quantum Hilbert spaces, our approach substantially enhances the expressiveness of non-linear modeling. Benchmarking our quantum-enhanced framework on a dataset targeting the $\mathtt{DYRK1A}$ kinase (a critical target for Alzheimer's disease), the $\mathtt{QMKL}$-$\mathtt{SVM}$ achieves an impressive Area Under the Curve ($\mathtt{AUC}$) score of $0.8750$, significantly outperforming classical state-of-the-art Gradient Boosting models ($\mathtt{AUC} = 0.8037$). Furthermore, we establish a theoretical and empirical pathway toward resolving classical data bottlenecks through projected quantum kernels ($\mathtt{PQK}$) and measurement accelerators. As quantum computing architecture matures, this framework paves the way for autonomous cognitive architectures and self-improving drug discovery pipelines, promising to unlock deeper insights across vast chemical spaces and to accelerate the development of life-saving therapeutics.

QBioFusion-QSAR: Morgan-Anchored Quantum Multiple Kernel Learning for Small-Data Ligand Classification

Small quantitative structure-activity relationship (QSAR) studies are difficult when close molecular analogues have different activity labels. This paper asks whether a quantum kernel can add similarity information to a Morgan/Tanimoto fingerprint model, and which molecules account for the change. QBioFusion-QSAR uses quantum multiple kernel learning (QMKL): a support vector machine combines a Morgan/Tanimoto kernel with a quantum fidelity kernel constructed from fold-local components derived from RDKit and Mordred descriptors and Deep-PK features. Linear and radial basis function descriptor kernels are included as classical controls. On the 54-molecule PsychLight-A benchmark, Morgan/Tanimoto was the strongest single representation. In the primary stratified five-fold evaluation, QMKL increased accuracy from 0.815 to 0.833 and Matthews correlation coefficient (MCC) from 0.613 to 0.645. Matched-regularization auditing attributed the change to N-Me-5-HT and N-Me-tryptamine changing from false-negative to true-positive predictions; activity-cliff subset MCC increased from 0.07 to 0.22. Repeating the five-fold protocol over ten random partitionings showed that learned QMKL did not exceed Morgan/Tanimoto on mean MCC; paired held-out bootstrap intervals for the matched comparison also span zero. These results support QBioFusion-QSAR as an auditable QMKL framework for identifying localized residual quantum-kernel contributions in small-data, activity-cliff-aware ligand classification.